FDA Orange Book ยท active-ingredient family
Halobetasol propionate
Halobetasol propionate: 5 brands, 13 generics; first approved Dec 17, 1990; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 13 ANDA applications approved.
Earliest patent expiry
Brands (NDA)
5
Generics (ANDA)
13
Listed patents
10
Next patent expiry
Nov 02, 2031
in 5 yr 1 mo
Brand (NDA) products
Originator applications
- BAUSCHNDA 2093552018
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.01% LOTION TOPICAL Rx - - LEXETTERLDMAYNE PHARMANDA 2105662018
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% AEROSOL, FOAM TOPICAL Discontinued - - LACER PHARMANDA 2081832015
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% LOTION TOPICAL Rx - - ULTRAVATERLDSUN PHARM INDS INCNDA 0199671990
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% CREAM TOPICAL Discontinued - - ULTRAVATERLDSUN PHARM INDS INCNDA 0199681990
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% OINTMENT TOPICAL Discontinued -
Generic (ANDA) products (13)
Abbreviated applications
- HALOBETASOL PROPIONATERSPADAGIS ISRAELANDA 2152662023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% AEROSOL, FOAM TOPICAL Rx - - HALOBETASOL PROPIONATEQUAGENANDA 2135602020
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% OINTMENT TOPICAL Rx AB - HALOBETASOL PROPIONATEPADAGIS ISRAELANDA 2114642020
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% LOTION TOPICAL Discontinued - - HALOBETASOL PROPIONATEENCUBEANDA 2099782018
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% OINTMENT TOPICAL Rx AB - HALOBETASOL PROPIONATERSCOSETTE PHARMS NCANDA 0781622007
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% CREAM TOPICAL Rx AB - HALOBETASOL PROPIONATECOSETTE PHARMS NCANDA 0777212006
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% OINTMENT TOPICAL Discontinued - - HALOBETASOL PROPIONATESUN PHARMA CANADAANDA 0772272005
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% CREAM TOPICAL Discontinued - - HALOBETASOL PROPIONATECOSETTE PHARMS NCANDA 0771092005
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% OINTMENT TOPICAL Rx AB - HALOBETASOL PROPIONATEFOUGERA PHARMSANDA 0770012004
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% CREAM TOPICAL Rx AB - HALOBETASOL PROPIONATEPADAGIS ISRAELANDA 0771232004
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% CREAM TOPICAL Rx AB - HALOBETASOL PROPIONATEFOUGERA PHARMSANDA 0769032004
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% OINTMENT TOPICAL Discontinued - - HALOBETASOL PROPIONATERSPADAGIS ISRAELANDA 0768722004
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% OINTMENT TOPICAL Rx AB - HALOBETASOL PROPIONATESUN PHARMA CANADAANDA 0769942004
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.05% OINTMENT TOPICAL Discontinued -
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 10478502 | in 5 yr 1 mo | ProductU-2625 | |
| 11986527 | in 5 yr 1 mo | U-2625 | |
| 11839656 | in 5 yr 1 mo | U-2625 | |
| 11957753 | in 5 yr 1 mo | Product | |
| 12076403 | in 5 yr 1 mo | Product | |
| 8809307 | in 5 yr 1 mo | Product | |
| 8962028 | in 6 yr 9 mo | ProductU-1775 | |
| 11020407 | in 10 yr 3 mo | ProductU-3143 | |
| 10857159 | in 10 yr 3 mo | Product | |
| 10857159*PED | in 10 yr 9 mo |
Approval history
FDA approval span
First approval
36 yr 5 mo ago
Most recent approval
3 yr 3 mo ago
Approvals span 1990โ2023 across 18 FDA applications.
Brand (NDA) 528%
Generic (ANDA) 1372%
Halobetasol propionate: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Halobetasol propionate
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo
